Comparative Cost-Effectiveness Research Easier Said Than Done, Experts Say
This article was originally published in The Gray Sheet
Executive Summary
Determining the comparative value of medical treatments sounds like a good idea, if only researchers could agree on how to do it
You may also be interested in...
White House Health Official Supports Cost-Effectiveness Research
Jeanne Lambrew, President Obama's top health policy expert, said comparative cost information on medical treatments could be a useful part of overall health care reform
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.